Genomic Characteristics and Clonal Evolution of EGFR-mutated Lung Adenocarcinoma-Transformed Squamous Carcinoma after EGFR-TKIs Treatment

被引：0
|
作者：
Kang, J. [1 ]
Yang, X. -N. [1 ]
Yan, L. -X. [2 ]
Yan, L. [3 ]
Yang, J. -J. [1 ]
机构：
[1] Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[2] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[3] Shanghai Tongshu Biotech Co Ltd, Shang Hai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
epidermal growth factor receptor; lung adenocarcinoma to; squamous cell carcinoma tra; drug resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-10
引用
收藏
页码：S335 / S335
页数：1
相关论文
共 50 条
  • [41] Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review
    Chen, Xiaoli
    Li, Dongmei
    Miao, Kun
    Shou, Tao
    Zhang, Wenjing
    MEDICINE, 2023, 102 (04) : E32697
  • [42] Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases
    Wang, H.
    Li, M.
    Xing, R.
    Wei, C.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1110 - S1110
  • [43] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
    Aguilar-Serra, J.
    Gimeno-Ballester, V
    Pastor-Clerigues, A.
    Milara, J.
    Trigo-Vicente, C.
    Cortijo, J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 637 - 646
  • [44] ANALYSIS OF THE EGFR MUTATIONS IN NON-SMALL CELL LUNG CANCER PATIENTS AFTER EGFR-TKIS TREATMENT
    Matsuo, Midori
    Nanae, Tomonaga
    Koichi, Izumikawa
    Hiroyuki, Yamaguchi
    Takaya, Ikeda
    Katsumi, Nakatomi
    Yoichi, Nakamura
    Kazuhiro, Tsukamoto
    Shigeru, Kohno
    RESPIROLOGY, 2010, 15 : 68 - 68
  • [45] Transformation from adenocarcinoma to squamous cell carcinoma associated with long-term administration of EGFR-TKIs
    Haruki, Tomohiro
    Nakanishi, Atsuyuki
    Matsui, Shinji
    Kidokoro, Yoshiteru
    Kubouchi, Yasuaki
    Takagi, Yuzo
    Taniguchi, Yuji
    Nakamura, Hiroshige
    MOLECULAR AND CLINICAL ONCOLOGY, 2020, 13 (06) : 1 - 3
  • [46] ACTIVATION OF THE BMP-BMPR PATHWAY CONFERRED RESISTANCE TO EGFR-TKIS IN LUNG SQUAMOUS CELL CARCINOMA PATIENTS WITH EGFR MUTATIONS
    Li, Zhenxiang
    Shen, Zhirong
    Fu, Jainchun Duan Shuai
    Liu, Zhentao
    Bai, Hua
    Zhang, Zeming
    Zhao, Jun
    Wang, Zhijie
    Wang, Jie
    ANTICANCER RESEARCH, 2015, 35 (07) : 4317 - 4317
  • [47] Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From EGFR-Mutated Adenocarcinoma After Osimertinib Treatment: A Case Report
    Takahashi, Shota
    Sato, Yuki
    Sato, Yoshiharu
    Hirabayashi, Ryosuke
    Hara, Shigeo
    Takahashi, Yutaka
    Tomii, Keisuke
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
  • [48] Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations
    Wang, Zhijie
    Shen, Zhirong
    Li, Zhenxiang
    Duan, Jianchun
    Fu, Shuai
    Liu, Zhentao
    Bai, Hua
    Zhang, Zemin
    Zhao, Jun
    Wang, Xiaodong
    Wang, Jie
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (32) : 9990 - 9995
  • [49] Nivolumab plus chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722)
    Park, Keunchil
    Yang, James Chih-Hsin
    Girard, Nicolas
    Mok, Tony
    Gainor, Justin
    Nakagawa, Kazuhiko
    Wu, Yi-Long
    Xu, Wanning
    Yang, Rong
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib
    Zhang, X.
    Wu, Y.
    Hu, Y.
    Zhang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S415 - S415
12345